Sulfadiazine
Neotrizine, Sulfadiazine, Sulfonamides Duplex (sulfadiazine) is a small molecule pharmaceutical. Sulfadiazine was first approved as Sulfadiazine on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, chancroid, enterobacteriaceae infections, and malaria amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Sulfadiazine (discontinued: Sulfadiazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfadiazine
Sulfadiazine sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULFADIAZINE SODIUM | Lederle Laboratories | N-004054 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| silvadene | New Drug Application | 2023-12-09 |
| silver sulfadiazene | New Drug Application | 2018-04-19 |
| silver sulfadiazine | New Drug Application | 2024-10-08 |
| ssd | New Drug Application | 2023-06-06 |
| ssd cream | New Drug Application | 2024-10-17 |
| sulfadiazine | ANDA | 2024-09-24 |
| thermazene | New Drug Application | 2024-08-09 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BA: Sulfonamides, topical
— D06BA01: Silver sulfadiazine
— D06BA51: Silver sulfadiazine, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01E: Sulfonamides and trimethoprim antibacterials for systemic use
— J01EC: Intermediate-acting sulfonamides
— J01EC02: Sulfadiazine
— J01EE: Combinations of sulfonamides and trimethoprim, incl. derivatives
— J01EE02: Sulfadiazine and trimethoprim
— J01EE06: Sulfadiazine and tetroxoprim
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | 5 | 4 | 6 | 10 | 24 |
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | 1 | 12 | 13 |
| Deafness | D003638 | EFO_0001063 | H91.9 | — | — | — | 1 | 12 | 13 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | 1 | 4 | 6 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 2 | 1 | — | 5 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | — | 1 | 1 | 2 | 1 | 5 |
| Communicable diseases | D003141 | — | — | 1 | 2 | 1 | 1 | — | 4 |
| Encephalitis | D004660 | HP_0002383 | — | — | 1 | — | 1 | 1 | 3 |
| Congenital toxoplasmosis | D014125 | EFO_0007220 | P37.1 | — | — | 1 | 1 | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | 1 | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | 2 | — | — | 3 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 1 | 2 | — | — | 3 |
| Chorioretinitis | D002825 | HP_0012424 | H30 | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 1 | — | — | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | 1 | — | — | 1 |
| Tibial fractures | D013978 | EFO_0003944 | S82.20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiodermatitis | D011855 | — | L58 | — | 2 | — | — | 2 | 4 |
| Medically unexplained symptoms | D000071896 | — | — | — | 1 | — | — | 3 | 4 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | 3 | 4 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | — | — | 1 | 3 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 2 | 3 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | — | 1 | — | — | 1 | 2 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | 1 | 2 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | — | — | — | 1 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Unilateral hearing loss | D046088 | HP_0009900 | — | — | — | — | — | 7 | 7 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 5 | 5 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 5 | 5 |
| Conductive hearing loss | D006314 | HP_0000405 | H90.2 | — | — | — | — | 3 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 3 | 3 |
| Speech sound disorder | D066229 | — | — | — | — | — | — | 2 | 2 |
| Mixed conductive-sensorineural hearing loss | D046089 | HP_0000410 | H90.8 | — | — | — | — | 2 | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 2 | 2 |
| Leprosy | D007918 | EFO_0001054 | A30 | — | — | — | — | 1 | 1 |
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfadiazine |
| INN | sulfadiazine sodium |
| Description | Sulfadiazine is a sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antimicrobial agent, an antiinfective agent, a coccidiostat, an antiprotozoal drug, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfadiazinate. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 68-35-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL439 |
| ChEBI ID | 9328 |
| PubChem CID | 5215 |
| DrugBank | DB00359 |
| UNII ID | 84CS1P306F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Sulfadiazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,314 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,015 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use